Data from 2552 patients randomised in the six included trials were analysed, and the authors identified a mean reduction in HbA1c level of −2.7 mmol/mol (–0.25%; 95% confidence interval −3.9 to −1.6) for those using SMBG, compared levels compared with those not using SMBG at 6 months. The investigators did not observe any between-group differences in systolic blood pressure (−0.2 mm Hg, 95% confidence interval −1.4 to 1.0), diastolic blood pressure (−0.1 mm Hg, −0.9 to 0.6), or total cholesterol level (−0.1 mol/L, 95% confidence interval −0.2 to 0.1).
Click here to access the study in full (no subscription required)
